Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's…
SPAC & De-SPAC Trading Stats (10/15/26) SPAC trading rebounded as $RFAI surged 13% and $FVN gained 8% while $ATII slid 12%, and De-SPAC volatility exploded with $ESLA jumping 68% and $SDST surging 55% on massive 1.63B volume. SPACs (DA partner): – $RFAI (Nanyang Biologics)…
Consensus price target: $12.00 (+1550.62% upside from $0.73)
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | — | $-13.06M |
| 2024 | $0 | — | $-8.85M |
| 2024 | $0 | — | $-7.31M |
Stock data for ESLA: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics